About

Here you'll find all the latest updates to the CMF site, as well as breaking news from the world of cardiometabolic diseases!

Latest Updates

Publications ▼
Publication thumbnail: GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lit Search

Find our February Literature Highlights here

Agarwal et al. - Effect of Finerenone on Ambulatory Blood Pressure in Chronic Kidney Disease in Type 2 Diabetes

Publication thumbnail: Effects of Finerenone in Persons with CKD and T2D are Independent of HbA1c at Baseline, HbA1c Variability, Diabetes Duration and Insulin Use at Baseline

Effects of Finerenone in Persons with CKD and T2D are Independent of HbA1c at Baseline, HbA1c Variability, Diabetes Duration and Insulin Use at Baseline

Publication thumbnail: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Publication thumbnail: Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP

Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP

Eli Lilly Logo

Tirzepatide Once Weekly for the Treatment of Obesity

FDA approves subcutaneous tirzepatide injection (Mounjaro™) for Type 2 Diabetes

New Ozempic Dose Approved by FDA

Hao Z et al.

Kadowaki T et al.

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes